What the NASH field needs, says Genfit CEO Pascal Prigent, is something like Hb1Ac for diabetes: a test that’s easy to do and that’s “commonly regarded as the right way to monitor the disease that ...

FDA accepts study protocol, providing green light for GENFIT to initiate Phase 2 clinical trial in pediatric NASH Elafibranor, the first molecule with positive results on registrational endpoint in ...

Genfit is set to terminate its phase 3 nonalcoholic steatohepatitis (NASH) trial after concluding it is unlikely to generate data to support approval. The action eliminates a long-time front-runner in ...

A Genfit drug that failed a pivotal study in the fatty liver disease NASH but still holds potential as a treatment for a rarer liver disorder will now move forward in the hands of Ipsen. That company ...

Data Safety Monitoring Board (DSMB) recommends the continuation of the RESOLVE-IT clinical trial without any modifications, based on the pre-planned review of safety data DSMB guidance remains ...

A company that had been potentially second in line to receive Food and Drug Administration approval for a drug to treat nonalcoholic steatohepatitis is now moving away from developing NASH drugs after ...

GENFIT (Euronext: GNFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect ...

Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland);September26, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the ...

Investors watching the changing fortunes of the drug companies in the race to successfully commercialize the first drug for NASH, or nonalcoholic steatohepatitis, is analogous to horseracing fans ...

If you go by the market's reaction, you'd think Genfit is out of the highly watched race to bring a drug for the liver disease NASH to market. Genfit Chief Executive Jean-Francois Mouney said that's a ...

Add Yahoo as a preferred source to see more of our stories on Google. Paris (Reuters) - French biopharmaceutical company Genfit said on Monday it is to launch a phase 3 study of its treatment for ...

Paris (Reuters) - French biopharmaceutical company Genfit said on Monday it is to launch a phase 3 study of its treatment for liver disease NASH by year-end as part of an accelerated approval ...